Cited by 230HER2/EGFR in Cancer ResearchBreast Lesions and CarcinomasCancer-related Molecular Pathways

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis

Open access

Andrechek, Eran R., Hardy, William R., Siegel, Peter M., Rudnicki, Michael A., Cardiff, Robert D., Muller, William J.·2000·Proceedings of the National Academy of Sciences

DOI 10.1073/pnas.97.7.3444PMC PMC16259

Open this paper in CoChat — free account

Abstract

The neu (c-erbB-2, Her-2) protooncogene is amplified and overexpressed in 20-30% of human breast cancers. Although transgenic mouse models have illustrated the role of Neu in the induction of mammary tumors, Neu expression in these models is driven by a strong viral promoter of questionable relevance to the human disease. To ascertain whether expression of activated Neu under the control of the endogenous promoter in the mammary gland could induce mammary tumors we have generated mice that conditionally express activated Neu under the transcriptional control of the intact endogenous Neu promoter. Expression of oncogenic neu in the mammary gland resulted in accelerated lobulo-alveolar development and formation of focal mammary tumors after a long latency period. However, expression of activated Neu under the normal transcriptional control of the endogenous promoter was not sufficient for the initiation of mammary carcinogenesis. Strikingly, all mammary tumors bear amplified copies (2-22 copies) of the activated neu allele relative to the wild-type allele and express highly elevated levels of neu transcript and protein. Thus, like human erbB-2-positive breast tumors, mammary tumorigenesis in this mouse model requires the amplification and commensurate elevated expression of the neu gene.

Integrity signals

Registry

Crossref · 10.1073/pnas.97.7.3444

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W. J., Jones, L. A., Holt, J. A., Wong, S., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J. A., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,817
Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells
Ullrich, A., Coussens, L. M., Hayflick, J. S., Dull, T. J., Gray, A., Tam, A. W., Lee, J., Yarden, Y., Libermann, T. A., Schlessinger, J., et al. (1984) · Nature · doi:10.1038/309418a0 · Cited by 2,751
Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu Oncogene
Coussens, L. M., Yang‐Feng, T. L., Liao, Y.-C., Chen, E., Gray, A., McGrath, J. P., Seeburg, P. H., Libermann, T. A., Schlessinger, J., Francke, U., et al. (1985) · Science · doi:10.1126/science.2999974 · Cited by 1,815
Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease
Guy, C. T., Cardiff, R., & Muller, W. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.3.954-961.1992 · Cited by 1,710
Self-citation
Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease.
Guy, C. T., Cardiff, R. D., & Muller, W. J. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.3.954 · Cited by 1,523
Requirement for neuregulin receptor erbB2 in neural and cardiac development
Lee, K., Simon, H. H., Chen, H., Bates, B., Hung, M., & Hauser, C. (1995) · Nature · doi:10.1038/378394a0 · Cited by 1,291
Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene.
Muller, W., Sinn, E., Pattengale, P., Wallace, R., & Leder, P. (1988) · Cell · doi:10.1016/0092-8674(88)90184-5 · Cited by 1,246
Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor
Yamamoto, T. S., Ikawa, S., Akiyama, T., Semba, K., Nomura, N., Miyajima, N., Saito, T., & Toyoshima, K. (1986) · Nature · doi:10.1038/319230a0 · Cited by 1,204
Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease.
Guy, C. T., Webster, M. A., Schaller, M. D., Parsons, T. J., Cardiff, R. D., & Muller, W. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.22.10578 · Cited by 1,193

Show all 38 references

Research works printed but not linked: 4

W C Dougall, X Qian, N C Peterson, M J Miller, A Samanta, M I Greene Oncogene 9, 2109–2123 (1994).
N E Hynes, D F Stern Biochim Biophys Acta 1198, 165–184 (1994).
R Zeillinger, F Kury, K Czerwenka, E Kubista, G Sliutz, W Knogler, J Huber, C Zielinski, G Reiner, R Jakesz Oncogene 4, 109–114 (1989).
T Ishikawa, M Kobayashi, M Mai, T Suzuki, A Ooi Am J Pathol 151, 761–768 (1997).

Sorted by citations

Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung Cancer
Cappuzzo, F., Hirsch, F. R., Rossi, E., Bartolini, S., Ceresoli, G. L., Bemis, L., Haney, J., Witta, S. E., Danenberg, K. D., Domenichini, I., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji112 · Cited by 1,538
The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis
Moasser, M. M. (2007) · Oncogene · doi:10.1038/sj.onc.1210477 · Cited by 1,291
ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
Arteaga, C. L., & Engelman, J. A. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.025 · Cited by 1,048
Modelling breast cancer: one size does not fit all
Vargo-Gogola, T. C., & Rosen, J. M. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2193 · Cited by 702
Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis
Grünert, S., Jechlinger, M., & Beug, H. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1175 · Cited by 682
Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA lossPreprint
Arun, G., Diermeier, S. D., Akerman, M., Chang, K.-C., Wilkinson, J. E., Hearn, S., Kim, Y., MacLeod, A. R., Krainer, A. R., Norton, L., et al. (2015) · Genes & Development · doi:10.1101/gad.270959.115 · Cited by 603
Oncogenes and Tumor Suppressor GenesPreprint
Lee, E. Y., & Muller, W. J. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a003236 · Cited by 575
Pten in stromal fibroblasts suppresses mammary epithelial tumours
Trimboli, A. J., Cantemir-Stone, C. Z., Li, F., Wallace, J. A., Merchant, A. S., Creasap, N., Thompson, J. C., Caserta, E., Wang, H., Chong, J.-L., et al. (2009) · Nature · doi:10.1038/nature08486 · Cited by 507
Structure–function relationship of estrogen receptor α and β: Impact on human health
Ascenzi, P., Bocedi, A., & Marino, M. (2006) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2006.07.001 · Cited by 522
Lung adenocarcinomas induced in mice by mutant EGF receptors foundin human lung cancers respondto a tyrosine kinase inhibitor orto down-regulation of the receptors
Politi, K., Zakowski, M. F., Fan, P.-D., Schonfeld, E. A., Pao, W., & Varmus, H. E. (2006) · Genes & Development · doi:10.1101/gad.1417406 · Cited by 478
Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis
Stingl, J., & Caldas, C. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2212 · Cited by 480
Targeted disruption of β1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction
White, D. E., Kurpios, N. A., Zuo, D., Hassell, J. A., Blaess, S., Mueller, U., & Muller, W. J. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.025 · Cited by 413
Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice
Anisimov, V. N., Berstein, L. M., Egormin, P. A., Piskunova, T. S., Popovich, I. G., Zabezhinski, M. A., Kovalenko, I. G., Poroshina, T. E., Semenchenko, A. V., Provinciali, M., et al. (2005) · Experimental Gerontology · doi:10.1016/j.exger.2005.07.007 · Cited by 402
Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium.
Flesken‐Nikitin, A., Choi, K., Eng, J. P., Shmidt, E. N., & Nikitin, A. Y. (2003) · PubMed · Cited by 271
Insights from transgenic mouse models of ERBB2-induced breast cancer
Ursini‐Siegel, J., Schade, B., Cardiff, R. D., & Muller, W. J. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2127 · Cited by 272
Effect of Conditional Knockout of the Type II TGF-β Receptor Gene in Mammary Epithelia on Mammary Gland Development and Polyomavirus Middle T Antigen Induced Tumor Formation and Metastasis
Forrester, E., Chytil, A., Bierie, B., Aakre, M. E., Gorska, A. E., Sharif‐Afshar, A., Muller, W. J., & Moses, H. L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3272 · Cited by 251
Par6–aPKC uncouples ErbB2 induced disruption of polarized epithelial organization from proliferation control
Aranda, V., Haire, T., Nolan, M. E., Calarco, J. P., Rosenberg, A. Z., Fawcett, J. P., Pawson, T. J., & Muthuswamy, S. K. (2006) · Nature Cell Biology · doi:10.1038/ncb1485 · Cited by 247
MCL-1 is a prognostic indicator and drug target in breast cancer
Campbell, K. J., Dhayade, S., Ferrari, N., Sims, A. H., Johnson, E. R., Mason, S. M., Dickson, A., Ryan, K. M., Kalna, G., Edwards, J., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0035-2 · Cited by 203
Mammary epithelial-specific disruption of the focal adhesion kinase blocks mammary tumor progression
Lahlou, H., Sanguin‐Gendreau, V., Zuo, D., Cardiff, R. D., McLean, G. W., Frame, M. C., & Muller, W. J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710091104 · Cited by 196
Akt1 and Akt2 Play Distinct Roles in the Initiation and Metastatic Phases of Mammary Tumor Progression
Dillon, R. L., Marcotte, R., Hennessy, B. T., Woodgett, J. R., Mills, G. B., & Muller, W. J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4287 · Cited by 169
Pathway Pathology
Rosner, A., Miyoshi, K., Landesman‐Bollag, E., Xu, X., Seldin, D. C., Moser, A. R., MacLeod, C. L., Shyamala, G., Gillgrass, A. E., & Cardiff, R. D. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64269-1 · Cited by 165
Grb2 and Shc Adapter Proteins Play Distinct Roles in Neu (ErbB-2)-Induced Mammary Tumorigenesis: Implications for Human Breast Cancer
Dankort, D. L., Maślikowski, B. M., Warner, N. E., Kanno, N., Kim, H. L., Wang, Z., Moran, M. F., Oshima, R. G., Cardiff, R. D., & Muller, W. J. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.5.1540-1551.2001 · Cited by 167
Loss of Par3 promotes breast cancer metastasis by compromising cell–cell cohesion
Xue, B., Krishnamurthy, K., Allred, D. C., & Muthuswamy, S. K. (2012) · Nature Cell Biology · doi:10.1038/ncb2663 · Cited by 159
Lysyl Oxidase–like Protein LOXL2 Promotes Lung Metastasis of Breast Cancer
Salvador, F., Martín, A. L., López‐Menéndez, C., Moreno‐Bueno, G., Santos, V., Vázquez-Naharro, A., Santamarı́a, P. G., Morales, S., Dubus, P. R., Muinelo‐Romay, L., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3152 · Cited by 152
Pin1 Regulates the Dynamics of c-Myc DNA Binding To Facilitate Target Gene Regulation and Oncogenesis
Farrell, A. S., Pelz, C., Wang, X., Daniel, C. J., Wang, Z., Su, Y., Janghorban, M., Zhang, X., Morgan, C. W., Impey, S., et al. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.01455-12 · Cited by 140
Transgenic mouse models of human breast cancer
Hutchinson, J. N., & Muller, W. J. (2000) · Oncogene · doi:10.1038/sj.onc.1203970 · Cited by 147
Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance
Wang, J., Li, B., Luo, M., Huang, J., Zhang, K., Zheng, S., Zhang, S., & Zhou, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01779-3 · Cited by 157
Changes in the Expression of Many Ets Family Transcription Factors and of Potential Target Genes in Normal Mammary Tissue and Tumors
Galang, C. K., Muller, W. J., Foos, G., Oshima, R. G., & Hauser, C. A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311887200 · Cited by 132
Self-citation
The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies
Freudenberg, J. A., Wang, Q., Katsumata, M., Drebin, J. A., Nagatomo, I., & Greene, M. I. (2009) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2009.05.001 · Cited by 135
Transforming Growth Factor–β Regulates Mammary Carcinoma Cell Survival and Interaction with the Adjacent Microenvironment
Bierie, B., Stover, D. G., Abel, T. W., Chytil, A., Gorska, A. E., Aakre, M. E., Forrester, E., Yang, H. H., Wagner, K., & Moses, H. L. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5597 · Cited by 124
PTHrP drives breast tumor initiation, progression, and metastasis in mice and is a potential therapy target
Li, J., Karaplis, A. C., Huang, D. C., Siegel, P. M., Camirand, A., Yang, X. F., Muller, W. J., & Kremer, R. B. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46134 · Cited by 125
ErbB2 Is Required for Muscle Spindle and Myoblast Cell Survival
Andrechek, E. R., Hardy, W. R., Girgis-Gabardo, A., Perry, R. L., Butler, R., Graham, F. L., Kahn, R., Rudnicki, M. A., & Muller, W. J. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.13.4714-4722.2002 · Cited by 123
Animal models of tumor immunity, immunotherapy and cancer vaccines
Ostrand‐Rosenberg, S. (2004) · Current Opinion in Immunology · doi:10.1016/j.coi.2004.01.003 · Cited by 122
ERRα mediates metabolic adaptations driving lapatinib resistance in breast cancer
Deblois, G., Smith, H. W., Tam, I. S., Gravel, S., Caron, M., Savage, P., Labbé, D. P., Bégin, L. R., Tremblay, M. L., Park, M., et al. (2016) · Nature Communications · doi:10.1038/ncomms12156 · Cited by 124
Botanical and Dietary Supplements for Menopausal Symptoms: What Works, What Does Not
GELLER, S. E., & Studee, L. (2005) · Journal of Women s Health · doi:10.1089/jwh.2005.14.634 · Cited by 122
ErbB2/Neu-Induced, Cyclin D1-Dependent Transformation Is Accelerated in p27-Haploinsufficient Mammary Epithelial Cells but Impaired in p27-Null Cells
Muraoka, R. S., Lenferink, A. E. G., Law, B. K., Hamilton, E., Brantley, D. M., Roebuck, L. R., & Arteaga, C. L. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.7.2204-2219.2002 · Cited by 116
Regulation of Mouse Mammary Gland Development and Tumorigenesis by the ERBB Signaling Network
Troyer, K. L., & Lee, D. C. (2001) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/a:1009560330359 · Cited by 114
Muc4/sialomucin complex, the intramembrane Er6B2 ligand, in cancer and epithelia: To protect and to survive
Carraway, K. L., Perez, A., Idris, N., Jepson, S., Arango, M. E., Komatsu, M., Haq, B., Price‐Schiavi, S. A., Zhang, J., & Carraway, C. A. (2002) · Progress in nucleic acid research and molecular biology · doi:10.1016/s0079-6603(02)71043-x · Cited by 111
Activation of anaplastic lymphoma kinase is responsible for hyperphosphorylation of ShcC in neuroblastoma cell lines
Miyake, I., Hakomori, Y., Shinohara, A., Gamou, T., Saito, M., Iwamatsu, A., & Sakai, R. (2002) · Oncogene · doi:10.1038/sj.onc.1205735 · Cited by 111
Persistent Activation of NF-κB in BRCA1-Deficient Mammary Progenitors Drives Aberrant Proliferation and Accumulation of DNA Damage
SAU, A. C., Lau, R., Cabrita, M. A., Nolan, E., Crooks, P. A., Visvader, J. E., & Pratt, M. A. C. (2016) · Cell stem cell · doi:10.1016/j.stem.2016.05.003 · Cited by 109
Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer
Yeon, C. H., & Pegram, M. D. (2005) · Investigational New Drugs · doi:10.1007/s10637-005-2899-8 · Cited by 101
The Nuclear Receptor Coactivator Amplified in Breast Cancer-1 Is Required for Neu (ErbB2/HER2) Activation, Signaling, and Mammary Tumorigenesis in Mice
Fereshteh, M., Tilli, M. T., Kim, S. E., Xu, J., O’Malley, B. W., Wellstein, A., Furth, P. A., & Riegel, A. T. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6702 · Cited by 98
β1-integrins signaling and mammary tumor progression in transgenic mouse models: implications for human breast cancer
Lahlou, H., & Muller, W. J. (2011) · Breast Cancer Research · doi:10.1186/bcr2905 · Cited by 96
Centrosome abnormalities, recurring deletions of chromosome 4, and genomic amplification of HER2/neu define mouse mammary gland adenocarcinomas induced by mutant HER2/neu
Montagna, C., Andrechek, E. R., Padilla‐Nash, H. M., Muller, W. J., & Ried, T. (2002) · Oncogene · doi:10.1038/sj.onc.1205146 · Cited by 94
Animal Models for Studying Prevention and Treatment of Breast Cancer
Welsh, J. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-415894-8.00040-3 · Cited by 101
Cooperativity of E-cadherin and Smad4 Loss to Promote Diffuse-Type Gastric Adenocarcinoma and Metastasis
Park, J. W., Jang, S. H., Park, D. M., Lim, N. J., Deng, C., Kim, D.-Y., Green, J. E., & Kim, H. K. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0192-t · Cited by 82
eIF4F suppression in breast cancer affects maintenance and progression
Nasr, Z., Robert, F., Porco, J. A. J., Muller, W. J., & Pelletier, J. (2012) · Oncogene · doi:10.1038/onc.2012.105 · Cited by 81
Transcriptional Control of the ERBB2 Amplicon by ERRα and PGC-1β Promotes Mammary Gland Tumorigenesis
Deblois, G., Chahrour, G., Perry, M.-C., Sylvain-Drolet, G., Muller, W. J., & Giguère, V. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2840 · Cited by 87
β-Catenin Signaling Is a Critical Event in ErbB2-Mediated Mammary Tumor Progression
Schade, B., Lesurf, R., Sanguin‐Gendreau, V., Bui, T., Deblois, G., O’Toole, S. A., Millar, E. K. A., Zardawi, S. J., López‐Knowles, E., Sutherland, R. L., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3925 · Cited by 80
MMTV mouse models and the diagnostic values of MMTV-like sequences in human breast cancer
Taneja, P., Frazier, D. P., Kendig, R. D., Maglic, D., Sugiyama, T., Kai, F., Taneja, N. K., & Inoue, K. (2009) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.09.31 · Cited by 85
Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancer
Knight, J. F., Lesurf, R., Zhao, H., Pinnaduwage, D., Davis, R. R., Saleh, S. M. I., Zuo, D., Naujokas, M. A., Chughtai, N., Herschkowitz, J. I., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1210353110 · Cited by 77
A genomic analysis of mouse models of breast cancer reveals molecular features ofmouse models and relationships to human breast cancer
Hollern, D. P., & Andrechek, E. R. (2014) · Breast Cancer Research · doi:10.1186/bcr3672 · Cited by 75
PTEN Deficiency in a Luminal ErbB-2 Mouse Model Results in Dramatic Acceleration of Mammary Tumorigenesis and Metastasis
Schade, B., Rao, T., Dourdin, N., Lesurf, R., Hallett, M. T., Cardiff, R. D., & Muller, W. J. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.018937 · Cited by 77
Models of breast cancer: is merging human and animal models the future?
Kim, J. B., O’Hare, M. J., & Stein, R. C. (2003) · Breast Cancer Research · doi:10.1186/bcr645 · Cited by 74
Mechanisms in Epithelial Plasticity and Metastasis: Insights from 3D Cultures and Expression Profiling
Jechlinger, M., Grünert, S., & Beug, H. (2002) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/a:1024090116451 · Cited by 78
Models of breast cancer: quo vadis, animal modeling?
Wagner, K. (2003) · Breast Cancer Research · doi:10.1186/bcr723 · Cited by 74
Cancer risk related to mammary gland structure and development
Russo, J., Hu, Y. F., da Silva, I. D. C. G., & Russo, I. H. (2001) · Microscopy Research and Technique · doi:10.1002/1097-0029(20010115)52:2 · Cited by 161
Targeted disruption of ErbB2/Neu in the mammary epithelium results in impaired ductal outgrowth
Andrechek, E. R., White, D., & Muller, W. J. (2004) · Oncogene · doi:10.1038/sj.onc.1208230 · Cited by 72
Biological and clinical significance of her2 overexpression in Breast Cancer
Kurebayashi, J. (2001) · Breast Cancer · doi:10.1007/bf02967477 · Cited by 70
Genetically Engineered Mouse Models of Mammary Intraepithelial Neoplasia
Cardiff, R. D., Moghanaki, D. M., & Jensen, R. A. (2000) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/a:1009534129331 · Cited by 70
Gene expression profiling of neu-induced mammary tumors from transgenic mice reveals genetic and morphological similarities to ErbB2-expressing human breast cancers.
Andrechek, E. R., Laing, M. A., Girgis-Gabardo, A., Siegel, P. M., Cardiff, R. D., & Muller, W. J. (2003) · PubMed · Cited by 65
The effect of melatonin treatment regimen on mammary adenocarcinoma development in HER‐2/neu transgenic mice
Anisimov, V. N., Alimova, I. N., Baturin, D. A., Popovich, I. G., Zabezhinski, M. A., Mantón, K. G., Semenchenko, A. V., & YASHIN, A. I. (2002) · International Journal of Cancer · doi:10.1002/ijc.10827 · Cited by 64
HER2 overcomes PTEN (loss)-induced senescence to cause aggressive prostate cancer
Ahmad, I., Patel, R., Singh, L. B., Nixon, C., Seywright, M. M., Barnetson, R. J., Brunton, V. G., Muller, W. J., Edwards, J., Sansom, O. J., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1101263108 · Cited by 63
Manifestation, mechanisms and mysteries of gene amplifications
Myllykangas, S., & Knuutila, S. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.07.045 · Cited by 64
Integrated analyses of murine breast cancer models reveal critical parallels with human disease
Rennhack, J. P., To, B., Swiatnicki, M., Dulak, C., Ogrodzinski, M. P., Zhang, Y., Li, C., Bylett, E., Ross, C. R., Szczepanek, K., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11236-3 · Cited by 66
Conditional Deletion of Shp2 in the Mammary Gland Leads to Impaired Lobulo-alveolar Outgrowth and Attenuated Stat5 Activation
Ke, Y., Lesperance, J., Zhang, E. E., Bard-Chapeau, E. A., Oshima, R. G., Muller, W. J., & Feng, G. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m607325200 · Cited by 61
Mammary Tumor-Associated RNAs Impact Tumor Cell Proliferation, Invasion, and Migration
Diermeier, S. D., Chang, K.-C., Freier, S. M., Song, J., Demerdash, O. E., Krasnitz, A., Rigo, F., Bennett, C. F., & Spector, D. L. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.08.081 · Cited by 59
Elevated Expression of DecR1 Impairs ErbB2/Neu-Induced Mammary Tumor Development
Ursini‐Siegel, J., Rajput, A. B., Lu, H., Sanguin‐Gendreau, V., Zuo, D., Papavasiliou, V., Lavoie, C. A., Turpin, J., Cianflone, K., Huntsman, D. D., et al. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00686-07 · Cited by 58
Mammary epithelial-specific disruption of c-Src impairs cell cycle progression and tumorigenesis
Marcotte, R., Smith, H. W., Sanguin‐Gendreau, V., McDonough, R. V., & Muller, W. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018861108 · Cited by 56
HER-2 overexpression differentially alters transforming growth factor-β responses in luminal versus mesenchymal human breast cancer cells
Wilson, C., Cajulis, E. E., Green, J. L., Olsen, T. M., Chung, Y.-A., Damore, M. A., Dering, J., Calzone, F. J., & Slamon, D. J. (2005) · Breast Cancer Research · doi:10.1186/bcr1343 · Cited by 56
Phosphatase and Tensin Homologue Deleted on Chromosome 10 Deficiency Accelerates Tumor Induction in a Mouse Model of ErbB-2 Mammary Tumorigenesis
Dourdin, N., Schade, B., Lesurf, R., Hallett, M. T., Munn, R. J., Cardiff, R. D., & Muller, W. J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5727 · Cited by 55
Chromatin Modifications Sequentially Enhance ErbB2 Expression in ErbB2-Positive Breast Cancers
Mungamuri, S. K., Murk, W. K., Grumolato, L., Bernstein, E., & Aaronson, S. A. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.09.009 · Cited by 54
Novel heteroduplex method using small cytology specimens with a remarkably high success rate for analysing EGFR gene mutations with a significant correlation to gefitinib efficacy in non-small-cell lung cancer
Oshita, F., Matsukuma, S., Yoshihara, M., Sakuma, Y., Ohgane, N., Kameda, Y., Saito, H., Yamada, K., Tsuchiya, E., & Miyagi, Y. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603396 · Cited by 52
ErbB2 Transgenic Mice: A Tool for Investigation of the Immune Prevention and Treatment of Mammary Carcinomas
Quaglino, E., Mastini, C., Forni, G., & Cavallo, F. (2008) · Current Protocols in Immunology · doi:10.1002/0471142735.im2009s82 · Cited by 51
SPRY2 loss enhances ErbB trafficking and PI3K/AKT signalling to drive human and mouse prostate carcinogenesis
Gao, M., Patel, R., Ahmad, I., Fleming, J., Edwards, J., McCracken, S. R., Sahadevan, K., Seywright, M. M., Norman, J. C., Sansom, O. J., et al. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201100944 · Cited by 51
Copy Number Aberrations in Mouse Breast Tumors Reveal Loci and Genes Important in Tumorigenic Receptor Tyrosine Kinase Signaling
Hodgson, J. G., Malek, T. B., Bornstein, S., Hariono, S., Ginzinger, D. G., Muller, W. J., & Gray, J. W. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0755 · Cited by 52
Deregulating MYC in a model of HER2+ breast cancer mimics human intertumoral heterogeneity
Risom, T., Wang, X., Liang, J. B., Zhang, X., Pelz, C., Campbell, L. G., Eng, J., Chin, K., Farrington, C. C., Narla, G., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126390 · Cited by 48
Solamargine upregulation of Fas, downregulation of HER2, and enhancement of cytotoxicity using epirubicin in NSCLC cells
Liang, C., Shiu, L., Chang, L., Sheu, H., & Kuo, K. (2007) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200700044 · Cited by 49
Mammalian Target of Rapamycin–Dependent Acinar Cell Neoplasia after Inactivation of Apc and Pten in the Mouse Salivary Gland: Implications for Human Acinic Cell Carcinoma
Diegel, C. R., Cho, K. R., El‐Naggar, A. K., Williams, B. O., & Lindvall, C. J. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1758 · Cited by 49
Signal Transduction in Transgenic Mouse Models of Human Breast Cancer—Implications for Human Breast Cancer
Marcotte, R., & Muller, W. J. (2008) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-008-9087-3 · Cited by 48
Mouse Models of Breast Cancer
Sakamoto, K., Schmidt, J. W., & Wagner, K. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2297-0_3 · Cited by 48
Integrin-linked kinase has a critical role in ErbB2 mammary tumor progression: implications for human breast cancer
Pontier, S. M., Huck, L., White, D. E., Rayment, J. H., Sanguin‐Gendreau, V., Hennessy, B. T., Zuo, D., St‐Arnaud, R., Mills, G. B., Dedhar, S., et al. (2010) · Oncogene · doi:10.1038/onc.2010.86 · Cited by 47
Lack of ductal development in the absence of functional estrogen receptor alpha delays mammary tumor formation induced by transgenic expression of ErbB2/neu.
Hewitt, S. C., Bocchinfuso, W. P., Zhai, J. L., Harrell, C., Koonce, L., Clark, J. A., Myers, P., & Korach, K. S. (2002) · PubMed · Cited by 46
TGF‐β promotes cell death and suppresses lactation during the second stage of mammary involution
Bierie, B., Gorska, A. E., Stover, D. G., & Moses, H. L. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21646 · Cited by 39
Epithelial Protein-Tyrosine Phosphatase 1B Contributes to the Induction of Mammary Tumors by HER2/Neu but Is Not Essential for Tumor Maintenance
Balavenkatraman, K. K., Aceto, N., Britschgi, A., Mueller, U., Bence, K. K., Neel, B. G., & Bentires‐Alj, M. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-11-0198 · Cited by 46
mTOR Directs Breast Morphogenesis through the PKC-alpha-Rac1 Signaling Axis
Morrison, M. M., Young, C. D., Wang, S., Sobolik, T., Sanchez, V. M., Hicks, D. J., Cook, R. S., & Brantley‐Sieders, D. M. (2015) · PLoS Genetics · doi:10.1371/journal.pgen.1005291 · Cited by 46
Functional Redundancy between β1 and β3 Integrin in Activating the IR/Akt/mTORC1 Signaling Axis to Promote ErbB2-Driven Breast Cancer
Bui, T., Rennhack, J. P., Mok, S., Ling, C., Perez, M., Roccamo, J., Andrechek, E. R., Moraes, C., & Muller, W. J. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.09.004 · Cited by 45
An EGR2/CITED1 Transcription Factor Complex and the 14-3-3σ Tumor Suppressor Are Involved in Regulating ErbB2 Expression in a Transgenic-Mouse Model of Human Breast Cancer
Dillon, R. L., Brown, S. T., Ling, C., Shioda, T., & Muller, W. J. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00866-07 · Cited by 45
p63 is a prosurvival factor in the adult mammary gland during post-lactational involution, affecting PI-MECs and ErbB2 tumorigenesis
Yallowitz, A. R., Alexandrova, E. M., Talos, F., Xu, S., Marchenko, N. D., & Moll, U. M. (2014) · Cell Death and Differentiation · doi:10.1038/cdd.2013.199 · Cited by 43
Concomitant Targeting of Tumor Cells and Induction of T-cell Response Synergizes to Effectively Inhibit Trastuzumab-Resistant Breast Cancer
Wang, Q., Li, S.-H., Wang, H., Xiao, Y. Q., Şahin, Ö., Brady, S. W., Li, P., Ge, H., Jaffee, E. M., Muller, W. J., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1339-t · Cited by 45
p120-catenin is essential for terminal end bud function and mammary morphogenesis
Kurley, S. J., Bierie, B., Carnahan, R. H., Lobdell, N. A., Davis, M. A., Hofmann, I., Moses, H. L., Muller, W. J., & Reynolds, A. B. (2012) · Development · doi:10.1242/dev.072769 · Cited by 46
Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells
Kim, A., Liu, B., Ordonez‐Ercan, D., Alvarez, K. M., Jones, L. D., McKimmey, C. C., Edgerton, S. M., Yang, X.-H., & Thor, A. D. (2005) · Breast Cancer Research · doi:10.1186/bcr1281 · Cited by 42
Reduction of Global H3K27me3 Enhances HER2/ErbB2 Targeted Therapy
Hirukawa, A., Singh, S., Wang, J. H., Rennhack, J. P., Swiatnicki, M., Sanguin‐Gendreau, V., Zuo, D., Daldoul, K., Lavoie, C. A., Park, M., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.105 · Cited by 43
Molecular alterations in sporadic breast cancer
Lerebours, F., & Lidereau, R. (2002) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(01)00191-3 · Cited by 41
Mutant and genetically modified mice as models for studying the relationship between aging and carcinogenesis
Anisimov, V. N. (2001) · Mechanisms of Ageing and Development · doi:10.1016/s0047-6374(01)00262-7 · Cited by 41
A novel role for 14–3–3σ in regulating epithelial cell polarityPreprint
Ling, C., Zuo, D., Xue, B., Muthuswamy, S. K., & Muller, W. J. (2010) · Genes & Development · doi:10.1101/gad.1896810 · Cited by 41
Dysregulation of Cell Polarity Proteins Synergize with Oncogenes or the Microenvironment to Induce Invasive Behavior in Epithelial Cells
Chatterjee, S., Seifried, L. A., Feigin, M. E., Gibbons, D. L., Scuoppo, C., Lin, W., Rizvi, Z. H., Lind, E. F., Dissanayake, D., Kurie, J. M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034343 · Cited by 40
Gene targeting of ErbB3 using a Cre‐mediated unidirectional DNA inversion strategy
Qu, S., Rinehart, C., Wu, H., Wang, S. E., Carter, B., Xin, H., Kotlikoff, M. I., & Arteaga, C. L. (2006) · genesis · doi:10.1002/dvg.20243 · Cited by 38
Dual role of AP-2? in ErbB-2-induced mammary tumorigenesis
J�ger, R., Friedrichs, N., Heim, I., B�ttner, R., & Schorle, H. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-004-4815-x · Cited by 38
Genetically Engineered Mice as Experimental Tools to Dissect the Critical Events in Breast Cancer
Menezes, M. E., Das, S. K., Emdad, L., Windle, J. J., Wang, X., Sarkar, D., & Fisher, P. B. (2014) · Advances in cancer research · doi:10.1016/b978-0-12-800249-0.00008-1 · Cited by 39

Authors: Andrechek, E. R., Hardy, W. R., Siegel, P. M., Rudnicki, M. A., Cardiff, R. D., & Muller, W. J.
Affiliations: University of California, Davis (US)
ORCID: Andrechek, Eran R.
Hardy, William R.
Siegel, Peter M.
Rudnicki, Michael A.
Cardiff, Robert D.
Muller, William J.
Venue: Proceedings of the National Academy of Sciences
Publisher: National Academy of Sciences
Published: 2000-03-14
Volume: 97
Issue: 7
Pages: 3444-3449
ISSN: 0027-8424 (ISSN-L)
1091-6490
DOI: 10.1073/pnas.97.7.3444
PMC: PMC16259
OpenAlex: W2041576667
Cited by: 230
References: 38
Citations by year: 2026: 5 · 2025: 4 · 2024: 5 · 2023: 7 · 2022: 2 · 2021: 6 · 2020: 10 · 2019: 7 · 2018: 6 · 2017: 7 · 2016: 8 · 2015: 9 · 2014: 12 · 2013: 9 · 2012: 8
FWCI: 5.59
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Proceedings of the National Academy of Sciences (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute (U01CA105490)
Topics: Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Health Sciences › Medicine › Pathology and Forensic Medicine › Breast Lesions and Carcinomas
Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Keywords: neu oncogene, c-erbB-2, HER2, gene amplification, mammary carcinogenesis, transgenic mouse model, conditional gene expression, endogenous promoter, breast cancer, oncogene overexpression
MeSH terms: Animals, Disease Models, Animal, Gene Amplification, Humans, Immunohistochemistry, Mammary Neoplasms, Experimental, Mice, Transgenic, DNA, Complementary, Genes, erbB-2, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks